# Nereid Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nereid-therapeutics

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.nereidtx.com
- Total disclosed funding: $50M
- Latest round: Seed (Nov 16, 2020)
- Investors on record: 1

## About

Nereid Therapeutics Inc. specializes in biopharmaceutical innovation, developing therapeutics that utilize biomolecular condensates and liquid-liquid phase separation technologies to enhance understanding of intracellular processes related to various diseases.Founded in 2020 and headquartered in Boston, US, Nereid Therapeutics Inc. focuses on creating novel therapeutics. The company has not undergone notable pivots or changes in its business strategy. Spiros Liras serves as the founder, and Michael Kauffman is the CEO. Nereid Therapeutics successfully raised USD 50 mn in Seed funding on November 16, 2020, led by Apple Tree Partners, bringing the total amount raised to USD 50 mn and current valuation to USD 53.96 mn.Nereid Therapeutics develops proprietary technologies centered on measuring and modulating liquid-liquid phase separation within mammalian cells. Their solutions are designed for pharmaceutical companies and academic institutions, aiding drug discovery efforts focused on complex diseases like cancer and neurodegenerative disorders. Their market presence extends across North America and Europe, where their technologies assist in the exploration of molecular interactions.Nereid Therapeutics generates revenue through collaborations and licensing agreements with pharmaceutical companies and research institutions. Their B2B model allows clients to access and integrate Nereid's technologies into their research workflows, with transaction structures including milestone payments and royalties based on successful product commercialization.Nereid Therapeutics plans to utilize the recent Seed funding of USD 50 mn to expand its product offerings and enhance its technological capabilities. The company aims to develop new therapeutics leveraging advanced methodologies in biomolecular condensates by the end of 2023. They are also looking to penetrate additional European markets and potentially expand to Asia by 2025, ensuring their innovations reach a broader range of clients in drug development.

## Funding rounds

- Seed, Nov 16, 2020, $50M — Apple Tree Partners

## Investors

- Apple Tree Partners (https://capitalatlas.ai/funds/apple-tree-partners) — Seed